Comparative Efficacy and Safety of Jintrolong and Other Long-Acting Growth Hormones for Growth Hormone Deficiency in East Asia: A Systematic Review and Network Meta-Analysis
Authors' conclusion
Jintrolong showed more favorable growth responses in 52 weeks compared with other long-acting growth hormones and daily GH without increasing safety risks.
Study context
- Population
- Pediatric GHD, East Asia5 studies
- Comparison
- Jintrolong vs other long-acting growth hormone (GH) vs daily GH
- Outcome
- Height velocity (HV)
Methodological detailsEnglish and Chinese databases searched from inception to 30 June 2025
- English and Chinese databases searched from inception to 30 June 2025
Pooled result
As reported in the abstract
Each group vs daily GHMD, cm/year (95% CI)
Jintrolong
0.86(0.13–1.6)
Pegpesen
−0.10(−0.53 to 0.32)
Somapacitan
−0.030(−0.52 to 0.46)
Further pooled results
| Outcome | MD (cm/year) (95% CI) | |
|---|---|---|
| Change in HV (cHV)Jintrolongvs Daily GH | 0.84 (0.077–1.60) | |
| −1012Difference, cm/year (linear scale) |
| Outcome | MD (95% CI) | |
|---|---|---|
| Change in height SDS (cHSDS)Jintrolongvs Daily GH | 0.080 (0.0013–0.16) | |
| −0.100.10.2Difference (linear scale) |
Safety
| Outcome | RR (95% CI) | |
|---|---|---|
| Adverse eventsJintrolongvs Daily GH | 1.0 (0.77–1.4) | |
| Adverse eventsPegpesenvs Daily GH | 1.0 (0.54–1.8) | |
| Adverse eventsSomapacitanvs Daily GH | 1.1 (0.99–1.3) | |
| Serious adverse eventsPegpesenvs Daily GH | 1.3 (0.03–42.34) | |
| Serious adverse eventsSomapacitanvs Daily GH | 2.6 (0.82–12) | |
| 0.050.21520Relative risk (log scale) |
| Outcome | RR (95% CI) |
|---|---|
| Serious adverse eventsJintrolong vs Daily GH | 0.0049 (∼0 to 3 216 099.58) |
Adverse events
- No significant differences in AE incidence
Serious adverse events
- No significant differences in SAE incidence
Original publication
Comparative Efficacy and Safety of Jintrolong and Other Long-Acting Growth Hormones for Growth Hormone Deficiency in East Asia: A Systematic Review and Network Meta-Analysis. Endocr Pract. Published 1 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →